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BACKGROUND. JC virus (JCV) is a polyomavirus that commonly infects humans
and is the causative agent of progressive multifocal leukoencephalopathy in
immune-compromised patients. An association between JCV and human cancers
long has been suspected, because this virus induces brain tumors in several ani-
mal models. The oncogenic potential of JCV is mediated by a transforming pro-
tein, the T-antigen (T-Ag), which is a multifunctional protein that transforms
cells through interactions with various growth-regulatory genes, including p53
and pRb, and by stabilizing b-catenin. Previously, the laboratory at the authors’
institution demonstrated that JCV is present frequently in the human gastroin-
testinal tract and may play a role in colorectal carcinogenesis. However, to date,
no studies have determined whether JCV sequences are present specifically in
gastric cancers. The current study was designed to investigate whether JCV
sequences and expression are found in human gastric cancers.
METHODS. DNA was extracted from 23 paraffin embedded and 14 frozen gastric
cancer specimens. For the detection of JCV gene sequences, polymerase chain
reaction amplifications were performed using gene-specific primers for T-Ag, VP-
1 (a JCV capsid gene), and the viral regulatory region (or transcriptional control
region). Immunohistochemical staining was performed with an anti-T-Ag mono-
clonal antibody to detect protein expression.
RESULTS. Twenty-one of 37 gastric cancers (57%) harbored JCV T-Ag sequences,
and 13 of 37 gastric cancers (30%) contained VP-1 sequences. T-Ag sequences
also were found in adjacent nonneoplastic mucosa. In addition, JCV regulatory
region sequences were present frequently in gastric cancers and adjacent non-
neoplastic mucosa. T-Ag protein expression was found in 9 of 23 gastric cancers
(39%), whereas no expression was observed in any of the nonneoplastic tissues.
CONCLUSIONS. To the authors’ knowledge, this is the first demonstration of the
presence of JCV T-Ag expression in human gastric cancers. These findings suggest
a possible role for this polyomavirus in gastric carcinogenesis. Cancer 2006;
107:481–8.  2006 American Cancer Society.
KEYWORDS: JC virus, polyomavirus, T-antigen, gastric cancer, chromosomal
instability.
A lthough the overall incidence of gastric cancer has decreasedsteadily in the last few decades, it remains the second most com-
mon cause of cancer-related deaths worldwide, with >600,000 deaths
anually.1 Analogous to other malignancies, gastric carcinogenesis also
is regarded as a multistep and multifactorial process. Gastric neo-
plasms are characterized by the successive accumulation of muta-
tions in genes that control epithelial cell growth and differentiation.2,3
The development of genomic instability is an important event in the
multistep progression of gastric carcinogenesis. Two apparently inde-
pendent pathways of genomic instability have been identified.4,5 The
Address for reprints: C. Richard Boland, MD, Divi-
sion of Gastroenterology, Department of Internal
Medicine, Baylor University Medical Center, 3500
Gaston Avenue, Dallas, TX 75206; Fax: (214) 818-
9292; E-mail: rickbo@baylorhealth.edu
Sponsored by the National Institutes of Health
(grant RO1-CA 98572) and through funds
provided by the Baylor Research Institute to
C. Richard Boland.
Received December 19, 2005; revision received
March 9, 2006; accepted March 28, 2006.
ª 2006 American Cancer Society
DOI 10.1002/cncr.22028
Published online 22 June 2006 in Wiley InterScience (www.interscience.wiley.com).
481
first pathway is characterized by tumors that have
widespread ‘‘microsatellite instability’’ (MSI), which is
the consequence of a defective DNA mismatch-repair
(MMR) system that occurs either because of germ-line
mutations in MMR genes or because of methylation-
induced silencing of hMLH1.6 Typically, MSI is identi-
fied in approximately 15% of sporadic gastric
cancers.7,8 It is believed that inactivation of hMLH1
through promoter hypermethylation is the cause of
the MSI phenotype in a majority of sporadic gastric
cancers.9
The second and more common pathway of geno-
mic instability is characterized by the sequential in-
activation of tumor suppressor genes and activation of
oncogenes. Tumors that evolve through this pathway
display chromosome instability, which is measured
through loss of heterozygosity events, chromosomal
amplifications, and translocations.10 Evidence for chro-
mosomal instability has been demonstrated in >50%
of gastric cancers and is typified by the presence of
loss of heterozygosity and rearrangements that involve
various chromosomal arms.11,12 Such chromosomal
aberrations are essential to the malignant transforma-
tion of a cell, because this process can create onco-
genes and delete tumor suppressor genes.13 Although
our current understanding of the mechanism for MSI
is quite clear, there is little agreement on the mechan-
istic basis for the chromosomal instability observed in
human cancers. In this context, it has been proposed
that the carcinogenic potential of the ‘‘transforming
antigen’’ (T-Ag), which is encoded by all polyoma-
viruses, may be sufficient by itself for the malignant
transformation of human embryonic cells.14 The poly-
omavirus family includes the simian virus 40 (SV40),
JC virus (JCV), and BK virus (BKV). All encode a ver-
sion of T-Ag, which is a multifunctional protein cap-
able of transforming cells both in vitro and in vivo by
interacting with p53 and the cell cycle regulator pRb,
leading to their destruction, and allowing unregulated
growth of the cancer cells.15–17
We previously provided evidence for the presence
of JCV in the normal gastrointestinal tract and colon
cancers in humans.18–21 More recently, we demon-
strated that JCV induced chromosomal instability in a
colon cancer cell line that expressed wild-type adeno-
matous polyposis coli (APC), p53, and b-catenin pro-
teins.22 JCV is a 5.12-kb, double-stranded, circular,
negatively supercoiled DNA virus. JCV genomes consist
of early and late coding regions that are separated by a
bidirectional, noncoding regulatory region. This regula-
tory region, also known as the transcriptional control
region (TCR), contains the promoter and enhancer ele-
ments for early and late transcription. The genes
encoded by the late coding region are 3 viral capsids
(VP-1, VP-2, and VP-3) and an agnoprotein. The large-
T (T-Ag) and small-t (t-Ag) antigens are encoded by
the early coding region of the viral genome.
JCV infects humans worldwide, and >80% of the
adult population carries antibodies against the virus.23
JCV has been considered an innocent and passive
passenger in humans; however, it can cause progres-
sive multifocal leukoencephalopathy in patients with
compromised immune status.24 It has been hypothe-
sized that JCV is oncogenic primarily because it en-
codes the T-Ag protein. JCV can cause aneuploid
tumors when it is injected into the brains of rodents.25
Furthermore, there is evidence for the presence of JCV
and T-Ag in high-grade human brain tumors.26
Our observations that JCV sequences are present
frequently in human colon cancers recently were
supported by several other independent labora-
tories.27–30 It has been suggested that, in addition to
the association of T-Ag with p53 and pRb, this onco-
genic protein also may interact with b-catenin, caus-
ing its stabilization, which dysregulates the WNT
signaling pathway in gastrointestinal cancers.27 Col-
lectively, these data suggest a possible role of JCV in
gastrointestinal carcinogenesis. The current study is
an extension of our previous work, and the objective
was to investigate whether JCV sequences also are
present in human gastric cancers, which, by infer-
ence, may help account for some degree of chromo-
somal instability observed in these neoplasms.
MATERIALS AND METHODS
Gastric Tissue Specimens
For this study, 37 sporadic gastric cancer tissues were
investigated, including 23 paraffin embedded tissue
blocks from the archives of Baylor University Medical
Center (Dallas, TX) and 14 fresh-frozen tissues from
Yonsei University (Seoul, South Korea). The diagnosis
for each of the samples was gastric adenocarcinoma
and was confirmed by expert pathologists from both
institutions. All patients were immunocompetent, and
none showed signs or symptoms of progressive multi-
focal leukoencephalopathy. This study was approved
by the Institutional Review Boards of both institutions.
DNA Extraction
Genomic DNA was extracted from paraffin-
embedded tissue sections or from frozen tissues by
using the QIAamp DNA mini kit (Qiagen Inc., Valen-
cia, CA) according to the manufacturer’s instructions
with some modifications. Extreme caution was exer-
cised to perform all preparatory polymerase chain
reaction (PCR) steps, including DNA extraction, in a
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separate room to avoid contamination issues with
PCR-amplified products.
Detection of JCV Genomic Sequences
PCR amplifications for JCV T-Ag, VP-1, and TCR were
performed by using the specific primer sequences listed
in Table 1, which shows that the primers T-Ag 154 for-
ward (F) and T-Ag 154 reverse (R) amplified a 154-base
pair (bp) sequence encoding the NH2-terminal region of
JCV T-Ag. Similarly, the primers VP-1F and VP-1R were
used to generate a 212-bp PCR product specific for the
VP-1 gene, which encodes for 1 of the viral capsid pro-
teins. Each PCR reaction consisted of a 25-L reaction
mixture that contained 0.2 g of genomic DNA,
1  HotStarTaq master mix (Qiagen Inc.), and 0.75 mM
of each primer (Invitrogen Life Technologies Inc., Carls-
bad, CA). The PCR reactions were carried out by using a
PTC 200 DNA Engine System (MJ Research Inc., Water-
town, MA). The PCR reactions were performed in a
separate room in the laboratory, as described above;
and, after amplification, the PCR products were sub-
jected to agarose gel electrophoresis in another part of
the laboratory. All PCR results subsequently were con-
firmed by sequencing the products using an ABI Prism
Big Dye Terminator version 1.1 Cycle Sequencing Kit on
an ABI Prism 3100 Avant Genetic analyzer (Applied Bio-
systems, Foster City, CA). The sequencing data obtained
were aligned with published JCV sequences to ensure
that the sequences were of JCV origin only and did not
match either BKV sequences or SV40 sequences.
Analysis of JCV Regulatory Region Sequences
Based on the regulatory region sequences, JCV can be
classified into 2 forms: the archetype and the tandem
repeat variants. Among the tandem repeat variants of
JCV, the most studied strain of JCV is Mad-131 (Fig. 1).
The noncoding regulatory region or TCR of Mad-1
JCV is characterized by the absence of 23-bp and 66-
bp sequences that otherwise are present in the arche-
type along with the presence of 98-bp tandem repeats.
More important, in our previous study, we found only
Mad-1 or rearranged forms of Mad-1 TCR sequences,
and we never found evidence for the archetype strain
of JCV in gastrointestinal cancers.20 Rearranged forms
of Mad-1 are characterized by a deletion or addition of
a 98-bp sequence that results in D98 or Mad-1A
sequences, respectively.20 For the current study, we used
PCR primers that were outside of the these regions of
rearrangement, which allowed us to amplify DNA
from multiple different JCV genotypes that yielded dif-
ferent sized PCR products. The primer sequences for
the amplification of TCR sequences are shown in
Table 1. PCR amplification was carried out on 0.2 g
of template DNA with a total reaction volume of
TABLE 1
Primer Sequences for Amplification and Detection
of JC Virus Genomes
Primer name/Position* Primer sequence
T-Ag gene
154 F: 4381–4408 50-ATGTATTCCACCAGGATTCCCATTCATC-30
154 R: 4511–4534 50-AGTTCTTGGAGACACCCCCTACAG-30
VP-1 gene
F: 1828–1848 50-TGTGCACTCTAATGGGCAAGC-30
R: 2019–2039 50-CTAGGTACGCCTTGTGCTCTG-30
TCR gene
F: 4986–5006 50-TACTTCTGAGTAAGCTTGGAG-30
R: 238–258 50-AAAACAGCTCTGGCTCGCAA-30
T-Ag indicates T-antigen; F, forward; R, reverse; TCR, transcriptional control region.
* Based on JC virus sequence Genebank accession no. NC_001699.
FIGURE 1. This is a schematic representation of the Mad-1 JC virus (JCV)
genome. Based on the regulatory region sequences, JCV can be classified into
2 forms, the archetype and the tandem repeat variant. Among tandem repeat
variants, the Mad-1 strain of JCV is the causative agent of progressive multi-
focal leukoencephalopathy. JCV (Mad-1) is a 5.13-Kb, double-stranded, circu-
lar, negatively supercoiled DNA virus. The noncoding regulatory region or the
transcriptional control region (TCR) of Mad-1 JCV is characterized by the
absence of 23-base pair (bp) and 66-bp sequences that are present otherwise
in the archetype along with the presence of 98-bp tandem repeats. The early
and late coding regions are separated by the bidirectional TCR, and transcrip-
tion in both directions initiates at the origin of replication (ori). The genes
encoded by the late coding regions are 3 viral capsids (VP-1, VP-2, VP-3) and
agnoprotein. The large T-antigen (T-Ag) and small t-Ag are encoded by the
early coding region of the viral genome.
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25 L. PCR reactions were comprised of 1  HotStar-
Taq master mix (Qiagen Inc.) and 0.5 mM of each pri-
mer (Invitrogen Life Technologies Inc.). Subsequent to
PCR, sequencing of the regulatory region was per-
formed to confirm further the presence of JCV and to
exclude the other 2 polyomaviruses (BKV and SV40),
which are distinct in their regulatory regions. All PCR
products were resolved on a 1.0% low-melting-point
agarose gel (Invitrogen Life Technologies Inc.) and
were purified by using a QIAamp gel extraction and
purification kit (Qiagen Inc.). Purified PCR products
thereafter were cloned into a pCR14-TOPO1 vector by
using a TOPO TA cloning kit (Invitrogen Life Technolo-
gies Inc.). Both strands of plasmid DNA subsequently
were sequenced by using an ABI Prism Big Dye Termi-
nator version 1.1 Cycle Sequencing Kit (Applied Biosys-
tems) on an ABI Prism 3100 Avant-Genetic analyzer
(Applied Biosystems). Along with each PCR amplifica-
tion of unknown TCR sequences from clinical tissues,
we amplified positive controls for various rearranged
forms of TCR using plasmid DNA samples that were
obtained from cloned, full-length JCV TCRs (Mad-1,
D98, and Mad-1A). The classification of JCV subtypes
from clinical tissues was performed according to the
scheme proposed by Jensen and Major.32
Immunohistochemical Staining for T-Ag in Gastric
Cancer Tissues
Immunohistochemical staining was performed only
on the paraffin embedded gastric cancer tissues. The
tissue sections used measured 4 m in thickness and
were mounted on positively charged slides. Tissue
sections were deparaffinized with xylene and rehy-
drated through gradient alcohol series. The sections
subsequently were immersed in 0.01 M citrate buffer
(pH 6.0) and were heated intermittently in a micro-
wave oven for a total of 20 minutes for nonenzymatic
antigen retrieval. Dual endogenous enzyme block
solution (Dako Cytomation Inc., Carpinteria, CA) was
applied to tissue sections for 10 minutes to block the
endogenous peroxidase. The primary antibody used
to detect specific T-Ag protein expression was a
mouse monoclonal antibody against SV40 large T-Ag
that cross reacts with JCV T-Ag (clone pAb416; 1:100
dilution; Oncogene Research Products, San Diego,
CA). Incubation of the primary antibody was per-
formed overnight and was followed by incubation in
Dako En Vision-labeled polymer (Dako Cytomation
Inc.) for 30 minutes. Staining was developed by reac-
tion with diaminobenzide chromogen for 5 to 10
minutes and then counterstaining for 5 minutes with
hematoxylin. The brown chromogen complexes were
indicative of T-Ag-specific expression in the gastric
cancer tissues.
RESULTS
Detection of JCV DNA Sequences in Gastric
Cancer Tissues
In the current study, we observed that 21 of 37
patients (57%) harbored JCV T-Ag sequences in the
neoplastic tissues and that 11 of 37 nonneoplastic
gastric tissues (30%) also harbored T-Ag sequences.
In addition, the viral capsid VP-1 sequences were
detected in 9 of 37 gastric cancer tissues (24%) and
in 7 of 37 nonneoplastic mucosae (19%) (Table 2).
Each PCR amplification was accompanied by ampli-
fying a positive control for JCV using the genomic
DNA from JCI cells (kindly provided by Dr. Kazuo
Nagashima, Hokkaido University, Sapporro, Japan),
which persistently is infected with JCV.33 The nega-
tive control, which involved the use of a water tem-
plate, was negative and excluded the likelihood of
laboratory contamination. Figure 2 shows a panel of
representative PCR amplifications of JCV sequences
from gastric cancer tissues and nonneoplastic tis-
sues. Because JCV T-Ag demonstates >70% homology
with SV40 and BKV T-Ag at the nucleotide level, our
PCR primers were designed specifically to amplify
JCV T-Ag sequences only. However, each of these
PCR amplicons was confirmed further through DNA
sequencing; and, in each instance, the presence of
JCV was validated.
Analysis of the JCV TCR
To confirm further the identity of the JCV sequences
that were observed in gastric cancer tissues and in
adjacent nonneoplastic tissues, all samples that were
amplified for T-Ag also were PCR amplified for the
detection of regulatory region, or TCR, sequences.
Again, after PCR amplification of these genomic se-
quences, the sequences were confirmed by using an
ABI Avant automated sequencer. The TCR sequences
that occur in the 98-bp tandem repeats of Mad-1 were
used as identification signatures, because these differ
substantially among JCV and the related SV40 and
BKV. Sixteen of 37 gastric cancer samples (43%) and
13 of 37 nonneoplastic tissue samples (35%) demon-
strated the presence of JCV Mad-1 and/or its rear-
ranged TCR forms, but the archetype strain was not
observed in any sample (Table 2, Fig. 3).
It is noteworthy that several samples (9 gastric
cancers and 5 nonneoplastic mucosae) harbored mul-
tiple regulatory strains of JCV in a single tissue speci-
men. These findings indicate the presence of different
strains of JCV, although the predominant sequence
rearrangements of the regulatory region were identi-
fied as either the D98 or the Mad-1 variant, similar to
what we observed in our previous study of colorectal
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cancers.20 There was no evidence of the archetypal
TCR of JCV in the gastric cancers. According to the
classification criteria stipulated by Jensen and Major,
the Mad-1 and Mad-1A TCRs are classified as Type
I-Repeat (I-R), and D98 is classified in the I-Single
(I-S) category.32 These data were another verification
of the identification of JCV in the gastric cancers,
because the TCRs are unique in JCV, BKV, and SV40.
Expression of Oncogenic T-Ag Protein Is Confined
to Cancer Cells
In this study, we observed JCV T-Ag expression fre-
quently in gastric cancer samples but never in non-
neoplastic tissue samples. Figure 4 and Table 2 show
the immunohistochemical data obtained from the
gastric cancers and nonneoplastic paraffin embedded
tissue sections that were stained for JCV T-Ag. Not
surprisingly, not every gastric cancer that was ampli-
fied for JCV T-Ag sequences demonstrated T-Ag pro-
tein expression. Overall, 9 of 23 (39%) cancer tissues
demonstrated positive T-Ag expression in the nuclei
of malignant cells. None of the tissue specimens that
were negative for T-Ag DNA sequences expressed JCV
T-Ag protein in the immunohistochemical analysis
(P < .01; Pearson chi-square test). T-Ag expression
was observed specifically in gastric cancer tissues
only and never was seen in the adjacent nonneoplas-
tic tissues, which is consistent with an active role for
this oncogenic protein in gastric carcinogenesis.
DISCUSSION
The results of this study demonstrate the presence of
JCV in human gastric cancer tissues. More important,
this work provides evidence that T-Ag expression is a
tumor-specific phenomenon. These observations are
in agreement with our previous findings, which also
have been supported by data from other laboratories
in reporting the presence of JCV DNA sequences in
TABLE 2
The Prevalence of JC Virus DNA Sequences and T-Antigen Protein
Expression in Gastric Cancer
No.
T-Ag VP-1 TCR
IHC for T-AgN T N T N T
1*  þ     
2*       
3y     I-R  ND
4y       ND
5*  þ  þ  I-R þ
6y þ  þ  I-R  ND
7* þ þ þ þ I-R I-R{ 
8*  þ  þ   þ
9*       
10*  þ   I-R{ I-R þ
11y þ þ   I-R, I-S I-R{, I-S ND
12y  þ    I-R, I-S ND
13y þ þ   I-R I-R{ ND
14*  þ  þ   
15y     I-R I-R, I-S ND
16*       
17*       
18y þ þ þ  I-R, I-S I-R, I-S ND
19*       
20*       
21*  þ    I-R þ
22y  þ     ND
23*       
24*  þ    I-R{, I-S þ
25*       
26y      I-R ND
27* þ þ þ þ I-R, I-S I-S þ
28y þ þ þ þ I-R I-R{ ND
29* þ þ þ þ I-R, I-S  þ
30* þ þ þ þ I-S I-R 
31* þ þ     þ
32y       ND
33*  þ     
34*       
35y       ND
36* þ þ    I-R{ þ
37y  þ  þ I-S I-S ND
T-Ag indicates T antigen; TCR, transcriptional control region; IHC, immunohistochemistry; N, adja-
cent nonneoplastic tissues; T, cancer tissues; I-R, type-I repeat; ND, not done; I-S, type-1 single.
* Paraffin-embedded tissues.
y Frozen tissues.
{Mad-1 and Mad-1A TCRs coexisted.
FIGURE 2. Polymerase chain reaction (PCR) amplification of T-antigen
(T-Ag) and VP-1 sequences of JC virus (JCV) in gastric cancer and nonneo-
plastic tissues. Top panel: The presence of 154-base-pair (bp) JCV T-Ag
sequences in a panel of representative samples showed that 21 of 37
tumors (57%) harbored T-Ag sequences, and these sequences were present
in 11 of 37 adjacent nonneoplastic tissues (30%). Bottom panel: Results
from the PCR amplification of an amplicon from VP-1, a viral capsid protein,
show that VP-1 sequences were positive in 9 of 37 gastric cancers (24%)
and in 7 of 37 nonneoplastic tissues (19%). N indicates adjacent nonneo-
plastic mucosa; T, gastric tumor; , negative control using water template;
þ, positive control from JCI cells.
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the mucosa of the gastrointestinal tract and in colon
cancers.18–20,27,30,34,35
It has been proposed that viruses may play an
important role as causative agents of cancer, but this
has been more difficult to demonstrate in humans
than in animal models. Evidence that supports the
role of viruses in human cancers has been emerging
at a constant pace, and associations have been made
between the presence of hepatitis B and C viruses
and hepatocellular carcinoma, the presence of SV40
and mesothelioma, and the presence of Epstein–Barr
virus in several malignancies.36–38 Furthermore, there
is mounting evidence that implicates SV40 and JCV
in certain types of human cancers.39 One of the rea-
sons for suspecting an oncogenic role for these viral
agents in human cancers may be attributed to the
presence of potent transforming genes in the puta-
tive oncogenic viruses. The most important of those
is the T-Ag, which is encoded by the 3 polyoma-
viruses: JCV, SV40, and BKV. T-Ag is a multifunctional
protein with the ability to bind and inactivate pRb
and p53. It has been suggested that, with these func-
tions, T-Ag can disrupt chromosomal integrity and
inactivate cell cycle check points that would limit
clonal expansion of such damaged cells.16,17
Several investigators previously reported that the
presence of JCV is associated strongly with aneuploid
brain tumors in animal models and in humans.25,40
In addition, elevated antibody titers to JCV have been
linked with aneuploid lymphocytes that were termed
‘‘rogue cells’’ by Neel et al.41 Previous reports from
our laboratory and from others have shown that JCV
T-Ag DNA sequences were present in 80% to 90% of
normal colonic tissues and colorectal cancers.18,19,27
T-Ag expression was never detected in normal colon
but was present exclusively in 63% of colorectal
cancers, supporting the oncogenic role of T-Ag in
these neoplasms.27 Recently, we also demonstrated
that JCV induced chromosomal instability in a
diploid colon cancer cell line with wild-type APC,
p53, and b-catenin.22 Analogous to human colorectal
cancer, gastric carcinogenesis commonly is associ-
ated with increased aneuploidy and chromosomal
instability. Based on these observations, the detection
of JCV sequences in gastric cancers and the tumor-
specific expression of T-Ag in neoplastic tissues (P <
.01; Pearson chi-square test) support our previous
observations in the colon and suggest a role for this
polyomavirus in gastric cancer.18,19
The mechanisms of transmission of JC viral infec-
tion are not clear; however, the presence of JCV in raw
sewage has suggested that the ingestion of contami-
nated water or food may represent a possible portal of
entry for JCV into the human body.42,43 Those findings
are all the more interesting in light of a recent report
of the detection of JCV T-Ag sequences and protein
expression in esophageal carcinomas.34 Along with
those findings and our previous studies, the current
report of the presence of JCV in gastric cancers pro-
vides further support for the possibility that the virus is
harbored in the gastrointestinal tract and may partici-
pate in carcinogenesis throughout the gut.
It has been observed that JCV genomes isolated
and sequenced directly from human tissues have a
highly variable, noncoding regulatory region, most
often referred to as the TCR. This regulatory region
can be divided into 7 distinct segments, starting with
the origin of replication (ori), followed by 6 regions
denoted alphabetically as regions a, b, c, d, e, and f.44
Among these, sequences represented by regions a, c,
e, and f are indicative of viral activity or functionality,
whereas the interspersed regions b and d inhibit effi-
cient transcription and replication.44 Duplication of
any single region or multiple regions in the a to e
boxes in tandem patterns are considered to enhance
viral activity.45 Specific TCR sequences affect the
level of viral transcription and replication; conse-
quently, 2 types of JCV strains have been identified
based on TCR structure.44 First among these is the
archetype, which is detected predominantly in urine
and sewage. The second type is the rearranged form
of JCV, called Mad-1, which is the principal form
detected in patients with progressive multifocal leu-
koencephalopathy.31 Recently, Jensen and Major pro-
posed a new scheme for classifying JCV according to
the structural variation of the TCRs.32 Those investi-
gators classified JCV strains into different ‘‘quad-
rants’’ based on the DNA sequence of the promoter.
I-S forms include sequence domains a, c, and e but
lack domains b and d. I-R forms all have 98-bp tan-
FIGURE 3. The results from polymerase chain reaction (PCR) amplification
of the regulatory region of JC virus (JCV) in gastric tissues are shown from
representative gastric tumor specimens (T) and corresponding nonneoplastic
tissues (N). Full-length D98, Mad-1, and Mad-1A (þ1, þ2, and þ3, respec-
tively) cloned into plasmids also were amplified with same primer pairs for
sizing the PCR products from the clinical tissues. The PCR amplifications
subsequently were confirmed by sequencing, and the majority of the sam-
ples showed D98 and rearranged forms of the Mad-1 transcriptional control
region. Archetypal JCV sequences were not found in any of the gastric can-
cers or adjacent nonneoplastic tissues.
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dem repeats, and this includes Mad-1 and other
strains. II-S forms include archetype strains. II-R
structures include duplication of the tandem repeats
present in II-S forms but with some variations in the
b and d segments. According to this classification,
Mad-1 belongs to type I-R. We previously reported
that only Mad-1 or its rearranged forms could be
found in nonneoplastic mucosa of the gastrointest-
inal tract and in malignant epithelial cells of colon
cancers.20 Similar to our previous observation in the
colon, in the current study, we observed that Mad-1
or type I-R was the most frequent form of JCV strain
present in gastric cancers, and we found no evidence
for II-S or the archetypal TCR. The sequence variabil-
ity of JCV TCR between and within specimens may
suggest that individuals are infected by different
strains or that there is an evolution of the diverse
viral sequences through multiple rounds of viral
replication. In this study, we did not find consistent
evidence for the presence of JCV T-Ag, VP-1, and
TCR sequences in every sample that expressed JCV
T-Ag protein. This partly may be because we do not
know whether JCV infection in the gastrointestinal
tract is ‘‘lytic,’’ which would suggest a productive
viral infection, or whether JCV merely acts a ‘‘passen-
ger.’’ Further studies will be required to address this
issue and may help explain why we detected TCR
sequences in only some of the T-Ag-positive gastric
cancers investigated in the current study.
In conclusion, the current results demonstrated
that the presence of JCV is frequent in human gastric
cancers and that the expression of the oncogenic
T-Ag is present in a tumor-specific manner. Clearly,
the mechanistic role of JCV in gastric cancer cannot
be ascertained from the current study, and future
studies will be needed to address these issues. None-
theless, these data clearly support an association
between JCV polyomavirus and gastric cancers and
provide compelling reasons to investigate whether
the presence of JCV correlates with increased geno-
mic instability in these neoplasms.
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